CRSP logo

CRISPR Therapeutics AG

CRSP
Healthcare|Biotechnology|CH
$50.07
+1.51 (+3.11%)
Tangible Book / Share
$17.04
Cash / Share
$23.49

Financials

Financial Snapshot

Market Cap
$4.86B
Enterprise Value
$5.44B
Revenue (TTM)
$25.2M
Net Income (TTM)
-$456.1M
Cash & Investments
$2.27B
Net Cash
$1.49B
Free Cash Flow (TTM)
-$379.2M
Operating CF (TTM)
-$374.6M
Debt/Equity
0.47

Cash Runway & Burn Rate

Cash on Hand
$2.27B
Quarterly Burn
$93.7M
Monthly Burn
$31.2M
Est. Runway
~24.3 quarters
MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$315.5M$239.8M$456.6M$943.8M$1.69B$2.38B$1.82B$1.69B$1.90B$1.98B$2.27B
Operating Cash Flow
-$55.3M-$70.1M-$96.2M$56.7M-$238.4M$539.0M-$495.7M-$260.4M-$142.8M-$345.0M-$374.6M
Free Cash Flow
-$58.3M-$77.9M-$99.0M$50.0M-$256.7M$457.3M-$532.9M-$269.8M-$144.7M-$345.9M-$379.2M
Capital Expenditure
-$3.0M-$7.8M-$2.8M-$6.7M-$18.4M-$81.7M-$37.2M-$9.5M-$1.9M-$914.0K-$4.6M
Financing Cash Flow
$183.2M$2.6M$315.9M$431.0M$1.02B$250.9M$38.6M$62.7M$332.0M$426.0M$720.0M

R&D Spending

R&D (TTM)
$283.3M
R&D Intensity
1125.4%
R&D Growth vs Prior
+6.8%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$5.2M$41.0M$3.1M$289.6M$719.0K$913.1M$436.0K$370.0M$35.0M$3.5M$25.2M
R&D Expense
$42.2M$69.8M$113.8M$179.4M$221.4M$340.6M$461.6M$387.3M$320.7M$265.3M$283.3M
R&D % of Revenue
817.9%170.3%3641.9%61.9%30790.3%37.3%105881.9%104.7%916.2%7559.2%1125.4%
SG&A
$31.1M$35.8M$48.3M$63.5M$85.7M$99.7M$102.5M$76.2M$73.0M$73.5M$68.9M

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$5.2M$41.0M$3.1M$289.6M$719.0K$913.1M$436.0K$370.0M$35.0M$3.5M$25.2M
Cost of Revenue
$42.2M$69.8M$113.8M$179.4M$269.4M$101.2M$110.3M$130.3M$110.3M$233.0M$195.5M
Gross Profit
-$37.1M-$28.8M-$110.6M$110.2M-$268.7M$811.9M-$109.8M$239.8M-$75.3M-$229.4M-$170.3M
R&D
$42.2M$69.8M$113.8M$179.4M$221.4M$340.6M$461.6M$387.3M$320.7M$265.3M$283.3M
SG&A
$31.1M$35.8M$48.3M$63.5M$85.7M$99.7M$102.5M$76.2M$73.0M$73.5M$68.9M
Operating Income
-$68.1M-$64.6M-$158.9M$46.7M-$354.4M$373.5M-$673.2M-$222.5M-$466.6M-$568.3M-$529.9M
Interest Expense
$8.1M$0.00$0.00—$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Pretax Income
-$22.7M-$66.6M-$164.4M$67.3M-$348.1M$379.5M-$650.5M-$150.7M-$362.7M-$578.0M-$453.6M
Net Income
-$23.2M-$68.4M-$165.0M$66.9M-$348.9M$377.7M-$650.2M-$153.6M-$366.3M-$581.6M-$456.1M
EPS (Diluted)
-1.89-1.71-3.441.17-5.294.70-8.36-1.94-4.34-6.47-4.74
EBITDA
-$13.7M-$61.6M-$155.4M$51.5M-$345.3M$397.5M-$626.3M-$130.9M-$343.4M-$558.5M-$459.8M
Shares Out. (M)
12.2640.0647.9656.9365.9580.3977.7579.2284.3689.9396.74

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$315.5M$239.8M$456.6M$943.8M$1.17B$923.0M$211.9M$389.5M$298.3M$355.2M$192.0M
Short-Term Investments
$0.00$0.00$0.00$0.00$521.7M$1.46B$1.60B$1.30B$1.61B$1.63B$2.08B
Total Current Assets
$320.2M$248.4M$466.4M$987.5M$1.72B$2.42B$1.85B$1.91B$1.94B$1.99B$2.29B
Total Assets
$345.0M$271.3M$489.0M$1.07B$1.83B$2.75B$2.24B$2.23B$2.24B$2.27B$2.56B
Total Current Liabilities
$22.0M$14.5M$27.7M$57.1M$94.3M$119.9M$121.1M$108.8M$87.8M$149.1M$141.0M
Long-Term Debt
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$188.2M$586.9M
Total Liabilities
$112.1M$83.5M$96.8M$127.3M$163.7M$352.4M$367.6M$346.8M$310.0M$343.4M$908.3M
Stockholders' Equity
$232.8M$187.8M$392.2M$939.4M$1.66B$2.40B$1.88B$1.88B$1.93B$1.92B$1.65B
Retained Earnings
-$57.1M-$125.4M-$291.6M-$224.7M-$573.6M-$195.9M-$846.1M-$999.7M-$1.37B-$1.95B-$2.27B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
-$55.3M-$70.1M-$96.2M$56.7M-$238.4M$539.0M-$495.7M-$260.4M-$142.8M-$345.0M-$374.6M
Capital Expenditure
-$3.0M-$7.8M-$2.8M-$6.7M-$18.4M-$81.7M-$37.2M-$9.5M-$1.9M-$914.0K-$4.6M
Free Cash Flow
-$58.3M-$77.9M-$99.0M$50.0M-$256.7M$457.3M-$532.9M-$269.8M-$144.7M-$345.9M-$379.2M
Investing Cash Flow
$31.9M-$8.3M-$2.8M$1.3M-$541.2M-$1.04B-$258.7M$374.6M-$280.5M-$31.8M-$443.3M
Financing Cash Flow
$183.2M$2.6M$315.9M$431.0M$1.02B$250.9M$38.6M$62.7M$332.0M$426.0M$720.0M
Issuance of Stock
$89.1M$2.6M$307.1M$415.0M$982.3M$213.3M$970.0K$62.7M$300.7M$426.0M$721.1M
Repurchase of Stock
$0.00$0.00-$57.0K$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Net Debt Issuance
$35.0M$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$10.8M$18.9M$35.0M$44.1M$66.0M$102.4M$97.9M$81.0M$86.6M$72.5M$69.7M
Net Change in Cash
$159.6M-$75.8M$216.9M$489.0M$236.7M-$245.5M-$715.9M$177.6M-$91.3M$49.3M-$101.7M

Dilution Tracker

Shares outstanding grew 36.4% over 5 years — significant dilution
Shares Outstanding
97M
5-Year Share Growth
+36.4%
Stock Issuance (TTM)
$721.1M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
12.2640.0647.9656.9365.9580.3977.7579.2284.3689.9396.74
Change vs Prior %
—226.8%19.7%18.7%15.8%21.9%-3.3%1.9%6.5%6.6%7.6%
Stock Issuance
$89.1M$2.6M$307.1M$415.0M$982.3M$213.3M$970.0K$62.7M$300.7M$426.0M$721.1M
Stock Repurchase
$0.00$0.00-$57.0K$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$10.8M$18.9M$35.0M$44.1M$66.0M$102.4M$97.9M$81.0M$86.6M$72.5M$69.7M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
-717.9%-70.3%-3541.9%38.1%-37369.7%88.9%-25186.7%64.8%-215.0%-6537.0%-676.5%
Operating Margin %
-1319.3%-157.7%-5087.8%16.1%-49295.5%40.9%-154394.7%-60.1%-1333.0%-16191.4%-2104.9%
Net Margin %
-449.3%-166.7%-5281.1%23.1%-48520.9%41.4%-149122.7%-41.5%-1046.4%-16569.8%-1812.1%
EBITDA Margin %
-266.1%-150.3%-4975.2%17.8%-48018.2%43.5%-143653.2%-35.4%-981.2%-15911.3%-1826.4%
FCF Margin %
-1129.5%-190.0%-3169.4%17.3%-35705.7%50.1%-122231.4%-72.9%-413.4%-9855.5%-1506.4%
ROE %
-10.0%-36.4%-42.1%7.1%-21.0%15.7%-34.7%-8.2%-19.0%-30.3%-25.6%
ROA %
-6.7%-25.2%-33.7%6.3%-19.1%13.7%-29.0%-6.9%-16.3%-25.7%-17.8%
ROIC %
-21.1%-25.2%-34.5%4.6%-20.3%14.1%-31.5%-10.4%-21.5%-26.6%-21.8%
R&D / Revenue %
817.9%170.3%3641.9%61.9%30790.3%37.3%105881.9%104.7%916.2%7559.2%1125.4%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
1990.7%693.9%-92.4%9169.8%-99.8%126893.2%-100.0%84762.4%-90.5%-90.0%
Gross Profit
-200.8%22.3%-284.2%199.6%-343.8%402.2%-113.5%318.3%-131.4%-204.9%
Operating Income
-164.8%5.1%-145.9%129.4%-858.3%205.4%-280.2%66.9%-109.7%-21.8%
Net Income
10.2%-194.6%-141.4%140.5%-621.8%208.3%-272.2%76.4%-138.4%-58.8%
EPS (Diluted)
-114.8%9.5%-101.2%134.0%-552.1%188.8%-277.9%76.8%-123.7%-49.1%
Operating Cash Flow
-193.1%-26.7%-37.3%158.9%-520.6%326.1%-192.0%47.5%45.2%-141.7%
Free Cash Flow
-200.1%-33.6%-27.1%150.5%-613.5%278.1%-216.5%49.4%46.4%-139.1%
R&D Expense
235.9%65.3%63.0%57.6%23.4%53.8%35.6%-16.1%-17.2%-17.3%
SG&A Expense
131.7%15.4%34.7%31.5%35.1%16.3%2.8%-25.7%-4.2%0.8%
Total Assets
116.4%-21.3%80.2%118.1%71.4%50.5%-18.5%-0.6%0.6%1.0%
Book Value / Share
2011.0%-75.3%74.0%111.2%46.1%25.2%-23.6%-1.5%-3.6%-6.7%
Debt
-100.0%0.0%0.0%0.0%16.9%266.3%8.4%-2.2%-6.3%76.5%
Diluted Shares
-58.2%226.8%19.7%18.7%15.8%21.9%-3.3%1.9%6.5%6.6%

Valuation

P/E (TTM)At Loss
P/S192.95
10Y Low / Med / High6.30 / 94.87 / 14043.89
P/B2.94
10Y Low / Med / High1.07 / 2.63 / 6.07
EV/EBITDAAt Loss
10Y Low / Med / High4.89 / 12.72 / 47.05
EV/Revenue216.30
10Y Low / Med / High5.54 / 92.74 / 12503.98
P/FCFAt Loss

Intrinsic Value Models (per share)

Tangible Book / Share
$17.04
Net Current Assets / Share
$14.19
Graham Net-Net
$14.10
Cash / Share
$23.49
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
-10.72-13.73-8.3149.52-28.9415.25-4.86-32.27-9.07-8.11-10.56
P/S Ratio
48.0922.89438.6111.4414043.896.307248.6213.4094.871343.50192.95
P/B Ratio
1.075.003.493.536.072.401.692.631.722.452.94
EV/EBITDA
4.89-11.34-5.8847.05-26.0412.72-5.10-36.74-9.45-8.51-11.84
EV/Revenue
-13.0117.05292.438.3612503.985.547322.3313.0092.741354.81216.30

Analyst Estimates & Quality

Altman Z-Score
2.36
Grey Zone
Piotroski F-Score
2
Weak

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$34.2M$120.0M$489.8M
Net Income-$441.0M-$366.4M-$287.5M
EPS$-4.50$-3.55$-2.00
# Analysts (EPS)13157

Revenue Segments

By Product

Segment202020212022202320242025
Collaborative Arrangement Material Rights$46.7M$46.7M————
Duchenne Muscular Dystrophy License$151.1M$151.1M————
Myotonic Dystrophy Type One License$51.3M$51.3M————
Myotonic Dystrophy Type One R And D Services$1.1M$1.1M————
Specified Target Option Material Right$11.8M$11.8M————
Exclusive License—$900.0M————
Collaborative Arrangement Material Rights Fourth Exclusive License—$6.7M————
Collaboration Revenue——$436.0K$370.0M$35.0M—
Grant——$762.0K$1.2M$2.3M$3.5M